NEW YORK (GenomeWeb News) – Knome has announced that its services division will now offer Omixon's targeted human leukocyte antigen typing capabilities as part of its whole genome and exome interpretation pipelines.

Omixon CEO Attila Berces said in a statement that the HLA typing service should help pharmaceutical companies that utilize Knome's services to identify drug response biomarkers, "shorten the time to approval, and reduce the risk of late-stage failures."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.